Summary
This 8-K filing from BeOne Medicines Ltd. (ONC), dated June 29, 2017, reports on the presentation of preliminary data from a Phase 1 clinical trial for its investigational anti-PD-1 antibody, BGB-A317. The data pertains to patients with advanced hepatocellular carcinoma (HCC), commonly known as liver cancer, and was presented at the ESMO 19th World Congress on Gastrointestinal Cancer. This update provides investors with early insights into the potential efficacy and safety of BGB-A317 in a specific oncology indication. The full details of these findings are available in the press release filed as an exhibit to this report.
Key Highlights
- 1BeOne Medicines announced preliminary Phase 1 data for BGB-A317, an anti-PD-1 antibody.
- 2The data focuses on patients with advanced hepatocellular carcinoma (HCC), or liver cancer.
- 3The findings were presented at the ESMO 19th World Congress on Gastrointestinal Cancer.
- 4BGB-A317 is an investigational drug, meaning it is still in the development and testing phase.
- 5This filing incorporates a press release containing the detailed preliminary data.
- 6The company is an emerging growth company and has elected to use the extended transition period for new accounting standards.